RESEARCH TRIANGLE PARK, N.C., April 30, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company plans to present at the following conferences: ...

Veri Medtech (Stock Ticker Symbol: "VRHI") announced today that it has relaunched its Veriheal.com healthcare technology platform.

RIDGEFIELD, Conn., April 30, 2025 ( GLOBE NEWSWIRE ) -- The Chefs' Warehouse, Inc. ( NASDAQ: CHEF ) ( the "Company" or "Chefs'" ) , a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its first quarter ended ...

SHANGHAI, April 30, 2025 ( GLOBE NEWSWIRE ) -- ECARX Holdings Inc. ( Nasdaq: ECX ) ( "ECARX" or the "Company" ) , a global mobility tech provider, today announced unaudited financial results for the quarter ended March 31, 2025.

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy.

WALTHAM, Mass., April 30, 2025 ( GLOBE NEWSWIRE ) -- Sionna Therapeutics, Inc.

MONTREAL, April 30, 2025 ( GLOBE NEWSWIRE ) -- Stingray Group Inc. RAY RAY.B ) ) will release its financial results for the fourth quarter ended March 31, 2025, on Tuesday, June 10, 2025, after the markets close. Management will hold a conference call to discuss the financial results the next ...

WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. ( Nasdaq: AVTX ) , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the ...

NAPLES, Fla., April 30, 2025 /PRNewswire/ --Beasley Broadcast Group, Inc. BBGI ( "Beasley" or the "Company" ) , a multi-platform media company, announced today that it will report its 2025 first quarter financial results before the market opens on Wednesday, May 7, 2025.

Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein ( a-syn ) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease ...